Company intelligence / Profile preview

Permatec Group

Steinhausen, Zug, Switzerland

Ownership: Private
Development stage: Other

Overview

Permatec was a Swiss pharmaceutical company specializing in the development and manufacture of transdermal and topical drug delivery systems. The company focused on creating innovative patch technologies and thin-film formulations to enhance the delivery and efficacy of various active pharmaceutical ingredients. In 2005, Permatec was acquired by Labtec GmbH, a move that integrated its transdermal expertise into what is now tesa Labtec. The company's legacy continues through the transdermal products and technologies now managed under the tesa SE umbrella.

Therapeutic areas: EndocrinologyNeurology
Modalities: Small moleculeTransdermal patchTopical drug delivery
Industry: Biotech

Beyond the preview

Go deeper on Permatec Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Permatec Group.

Explore the full profile